KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to 72267.92%.

  • Vir Biotechnology's EBITDA Margin fell 625492600.0% to 72267.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 3253.6%, marking a year-over-year decrease of 24789300.0%. This contributed to the annual value of 791.27% for FY2024, which is 27700.0% up from last year.
  • Per Vir Biotechnology's latest filing, its EBITDA Margin stood at 72267.92% for Q3 2025, which was down 625492600.0% from 9754.28% recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's EBITDA Margin peaked at 82.26% during Q1 2022, and registered a low of 72267.92% during Q3 2025.
  • For the 5-year period, Vir Biotechnology's EBITDA Margin averaged around 6583.54%, with its median value being 828.12% (2023).
  • As far as peak fluctuations go, Vir Biotechnology's EBITDA Margin skyrocketed by 81102500bps in 2022, and later crashed by -625492600bps in 2025.
  • Over the past 5 years, Vir Biotechnology's EBITDA Margin (Quarter) stood at 70.35% in 2021, then crashed by -533bps to 304.6% in 2022, then plummeted by -172bps to 828.12% in 2023, then fell by -14bps to 946.74% in 2024, then crashed by -7533bps to 72267.92% in 2025.
  • Its EBITDA Margin was 72267.92% in Q3 2025, compared to 9754.28% in Q2 2025 and 4602.47% in Q1 2025.